Akari Therapeutics Plc (AKTX): debt financing — Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan

Akari Therapeutics Plc

Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.
Chairman Dr. Huh purchased $1,250,000 principal note for $1,000,000, paying $162,567 cash and cancelling $837,433 Peak Bio loan.
Extended expiration of Series A Warrants on 1,973,211 ADSs by 48 months from original expiry.
Paid Paulson Investment Company a 5% advisory fee ($70K) on ~$1.4M gross cash proceeds.
Notes are unsecured; proceeds used for general corporate purposes.

item 1.01 item 1.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Akari Therapeutics Plc incurred debt of $2,826,250 maturing 12-month anniversary of the respective Closing Dates.

Principal: $2,826,250
Maturity: 12-month anniversary of the respective Closing Dates
Event: incurrence

Exact text from the filing

the Company completed its first tranche of closings of the Offering and issued Notes with an aggregate purchase price of $2,261,000 and an aggregate principal amount of $2,826,250

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0001641172-25-025104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.